

FDA Approved Cell & Gene Therapies



ARM Foundation
for Cell & Gene Medicine

KYMRIAH

- Approved August 30, 2017
- One-time treatment for children and young adults up to 25 years of age with B-Cell acute lymphoblastic leukemia that is refractory or twice relapsed after treatment
- CAR-T cell therapy

YESCARTA

- Approved October 18, 2017
- One-time treatment for youth and adults, aged 18 and over with refractory or relapsing large B-cell lymphoma
- CAR-T cell therapy

LUXTURNA

- Approved December 19, 2017
- One-time treatment for children and adults with confirmed “biallelic RPE65 mutation-associated retinal dystrophy,” an inherited form of impaired vision that may progress to complete blindness
- Gene therapy

ZOLGENSMA

- Approved May 24, 2019
- AAV vector-based gene therapy for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy type 1
- Gene therapy

TECARTUS

- Approved June 24, 2020
- One-time treatment for adults with relapsed or refractory mantle cell lymphoma (MCL)
- CAR-T cell therapy

BREYANZI

- Approved February 5, 2021
- One-time treatment for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
- CAR-T cell therapy

ABECMA

- Approved March 26, 2021
- One-time treatment for adults with relapsed or refractory multiple myeloma after at least four prior lines (different types) of therapy
- CAR-T cell therapy

